Hbsag Negatif, Antihbcıgg Pozitif Hastada Allojenik Kemik İliği Nakli Sonrası Rituksimaba Bağlı Hepatit B Reaktivasyonu
Özet
Referanslar
Ceylan, M, Turken M, Singil S, Adar P, Köse Ş. İmmunsupresif tedavi alan hastalarda hepatit B reaktivasyonu riskinin değerlendirilmesi. İzmir Tıp Fakültesi Dergisi, 2022 1(3), 112-116.
Uyanikoglu A. Chronic Hepatitis B Infection. J Infect Dis Ther 2014, 2:2 http://dx.doi.org/10.4172/2332-0877.1000133.
Aygen B, Demir AM, Gümüş M, et al. Immunosuppressive therapy and the risk of hepatitis B reactivation: Consensus report. Turkish Journal of Gastroenterology 2018, 29, 259-269.
Yıldız O. İmmünosüprese hastalarda HBV reaktivasyonuna yaklaşım. Klimik Dergisi 2016.
Viral Hepatitle Savaşım Derneği. Türkiye Hepatit B Tanı ve Tedavi Kılavuzu 2023.
Ali FS, Nguyen MH, Hernaez R, et al. AGA Clinical Practice Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation in At-Risk Individuals. Gastroenterology. 2025;168(2):267-284.
Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD hepatitis B guidance. Hepatology 2018, 67(4), 1560-1599.
Cholongitas E, Haidich AB, Apostolidou-Kiouti F, Chalevas P, Papatheodoridis GV. Hepatitis B virus reactivation in HBsAg-negative, anti-HBc-positive patients receiving immunosuppressive therapy: A systematic review. Annals of Gastroenterology 2018, 31(4), 480-490. https://doi.org/10.20524/aog.2018.0266.
Uyanikoglu A,Sert U, Cetin B,Yenice N. The Distribution Clinical and Demographic Features of HBsAg Positive Patients in Şanlıurfa [Şanlıurfa Yöresinde HBsAg Pozitif Hastaların Klinik Dağılımı ve Demografik Özellikleri]. Viral Hepatitis Journal 2015; 21(3): 89-93. Doi: 10.4274/vhd.54227.
Uyanıkoğlu A, Sert U, Nar H, Yenice N. Occult Hepatitis B Reactivation After Chemoteraphy: A Case Report [Kemoterapi Sonrası Okkült Hepatit B Reaktivasyonu: Olgu]. Viral Hepatit Dergisi [Viral Hepatitis Journal]. Viral Hepatitis Journal 2015; 21(2): 56-58. Doi: 10.4274/vhd.36025.
Lan TY, Chang TW, Tseng TC, Lee TJ, Kao JH, Cheng CF, Huang SC, Shen CY, Lu CH, Yang HC, Li KJ, Hsieh SC. Risk of rituximab-induced hepatitis B flare after antiviral discontinuation in rheumatic patients with chronic hepatitis B virus. Clin Exp Rheumatol. 2024 Sep;42(9):1830-1837. doi: 10.55563/clinexprheumatol/qh1gj3.
Sarin SK, Kumar M, Eslam M, George J, Al Mahtab M, Akbar SMF, et al. Liver diseases in the Asia-Pacific region: A Lancet Gastroenterology & Hepatology Commission. The Lancet Gastroenterology & Hepatology 2020, 5(2), 167-228.
European Association for the Study of the Liver (EASL). EASL clinical practice guidelines: Management of hepatitis B virus infection. Journal of Hepatology 2022, 77(2), 447-485.
Ali FS, Nguyen MH, Hernaez R, Huang DQ, Wilder J, Piscoya A, Simon TG, Falck-Ytter Y. AGA Clinical Practice Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation in At-Risk Individuals. Gastroenterology. 2025 Feb;168(2):267-284. doi: 10.1053/j.gastro.2024.11.008.
Celsa C, Rizzo GEM, Di Maria G, Enea M, Vaccaro M, Rancatore G, Graceffa P, Falco G, Petta S, Cabibbo G, Calvaruso V, Craxi A, Camma C, Di Marco V. What is the benefit of prophylaxis to prevent HBV reactivation in HBsAg-negative anti-HBc-positive patients? Meta-analysis and decision curve analysis. Liver Int. 2024 Nov;44(11):2890-2903. doi: 10.1111/liv.16064.
Kuo MH, Tseng CW, Ko PH, Wang ST, Lu MC, Tung CH, Tseng KC, Huang KY, Lee CH, Lai NS. HBV reactivation in HBsAg-/HBcAb+ rheumatoid arthritis patients receiving biologic/targeted synthetic DMARDs. Liver Int. 2024 Feb;44(2):497-507. doi: 10.1111/liv.15793.
De Pauli S, Grando M, Miotti G, Zeppieri M. Hepatitis B virus reactivation in patients treated with monoclonal antibodies. World J Virol. 2024 Mar 25;13(1):88487. doi: 10.5501/wjv.v13.i1.88487.
Tonnini M, Solera Horna C, Ielasi L. Prevention of hepatitis B reactivation in patients with hematologic malignancies treated with novel systemic therapies: Who and Why? World J Gastroenterol. 2024 Feb 7;30(5):509-511. doi: 10.3748/wjg.v30.i5.509. PMID: 38414584; PMCID: PMC10895601.
